CHINA VS INDIA FOR TIL THERAPY:
WHICH IS BETTER FOR SOLID TUMOURS?
TIL therapy is one of the most closely watched cell-based immunotherapies for solid tumours. This guide compares both corridors honestly โ access, eligibility, cost and safety โ before any travel decision.
analyticsAt a Glance
- check_circleChina: broader TIL and solid tumour cell therapy trial ecosystem โ most active for melanoma, cervical, lung and GI cancers.
- check_circleIndia: affordable diagnostics, surgery, systemic therapy and follow-up โ still at an earlier stage for direct TIL delivery.
- check_circleTIL therapy is largely investigational outside the approved melanoma setting in some countries.
- check_circleManufacturing takes weeks โ not suitable for rapidly progressing or unstable disease.
What TIL Therapy Involves
TIL therapy rescues and amplifies immune cells already inside the tumour. Unlike CAR-T, which succeeded first in blood cancers, TIL therapy is built for solid tumours. The pathway involves tumour tissue collection, laboratory expansion over several weeks, lymphodepleting chemotherapy, infusion and immune support.
Tissue Collection
A tumour lesion is surgically removed or biopsied to collect viable tissue containing immune cells.
Laboratory Expansion
Tumour-infiltrating lymphocytes are isolated and expanded into very large numbers in a specialised GMP laboratory over several weeks.
Lymphodepleting Chemotherapy
Short chemotherapy prepares the body to receive and expand the new cells.
Infusion and Immune Support
The expanded cells are infused back into the patient, often followed by interleukin-2 or other immune support and close inpatient monitoring.
China vs India: Strengths at a Glance
They are good at different parts of the same journey. The better destination depends on what the patient actually needs next.
China: Broader TIL and Cell Therapy Trials
Major cancer centres run TIL, TCR-T, solid tumour CAR-T, CAR-NK and combination studies with significant GMP manufacturing capacity. Selected patients may be evaluated for TIL protocols combined with PD-1 inhibitors, cytokines or targeted agents. Access depends entirely on trial criteria and specialist review.
India: Evaluation, Surgery and Support Base
Experienced cancer surgeons, oncologists, pathology services, molecular labs and affordable hospital care, with fluent English communication. India's strongest role today is second opinion, diagnosis, molecular profiling, surgical biopsy, tumour board review, systemic therapy and post-cell-therapy monitoring.
How CancerFax Helps
A structured pathway rather than a sales pitch โ matching the clinical situation to the most appropriate corridor.
- 1
Report Collection and Case Understanding
Diagnosis, treatment history, current status and goals are reviewed to see whether cell therapy is realistic at all.
- 2
Clinical Suitability Check
The case is matched against relevant TIL or cell therapy options, hospitals and trials based on diagnosis, biomarkers and prior treatment.
- 3
Second Opinion and Centre Review
Reports are shared with appropriate oncology or trial teams in China, India or elsewhere for structured feedback.
- 4
Treatment Planning and Cost Clarity
Guidance on likely pathway, tissue requirements, manufacturing timelines, cost ranges, stay duration and logistics.
- 5
Travel and Coordination
Admission communication, interpreter needs, travel guidance and post-treatment follow-up planning.
Frequently Asked Questions
TIL Therapy: China vs India
Is TIL therapy better in China or India?
For direct access to TIL therapy and solid tumour cell therapy trials, China currently has the broader ecosystem. For affordable diagnosis, surgery, molecular testing, systemic therapy and supportive care, India is often stronger. Many patients benefit from a combined pathway decided after specialist review.
Is TIL therapy approved in China or India?
For most solid tumours, TIL therapy is investigational in both countries and accessed mainly through clinical trials or hospital protocols. In the United States, one TIL product is approved for advanced melanoma. Approval and access may change over time, so current status should be confirmed for your specific cancer type.
Which cancers can TIL therapy be used for?
Research is most advanced in melanoma, with active study in cervical, non-small cell lung, head and neck, and some gastrointestinal cancers. Eligibility depends on stage, prior treatment, tumour tissue availability and trial criteria.
What happens if I am not eligible for TIL therapy?
CancerFax helps explore other relevant options โ approved immunotherapy, targeted therapy after molecular testing, other cell therapy where applicable, or different clinical trials. The aim is a medically appropriate next step, not pushing a single therapy.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Comparing China and India for TIL Therapy?
Share your pathology, imaging and treatment history. Our clinical team will assess whether cell therapy is realistic for your case and identify which corridor โ China, India or a combined pathway โ best suits your situation.
This information is for patient education and navigation support only. All treatment decisions must be made in consultation with a qualified oncologist.